Cooper Companies (NASDAQ:COO) Price Target Lowered to $58.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan lowered Cooper Companies’ price target to $58 from $71 while maintaining a neutral rating. Other analysts also cut targets, leaving the stock with a consensus “Hold” rating and an average target of $73.47.
• Shares fell 13.5% to $54.89 after quarterly revenue of $1.07 billion missed expectations, despite adjusted EPS of $1.15 exceeding estimates. Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 was also below analyst expectations.
• The board authorized a $3 billion share-repurchase program, potentially covering up to 22.7% of outstanding shares, as management seeks to support shareholder value amid limited growth and valuation pressure.

Cooper Companies (NASDAQ:COO - Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $71.00 to $58.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a "neutral" rating on the medical device company's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 5.66% from the stock's current price.

A number of other equities analysts have also recently commented on the company. UBS Group reduced their price target on Cooper Companies from $75.00 to $66.00 and set a "neutral" rating for the company in a report on Thursday. Piper Sandler downgraded Cooper Companies from an "overweight" rating to a "neutral" rating and set a $59.00 target price for the company. in a research note on Thursday. Needham & Company LLC decreased their target price on Cooper Companies from $86.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a report on Wednesday, May 27th. Finally, Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $73.47.

Cooper Companies Stock Down 13.5%

COO traded down $8.59 during trading on Thursday, reaching $54.89. 6,560,720 shares of the stock were exchanged, compared to its average volume of 2,372,654. The stock has a market cap of $10.71 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The stock's 50 day moving average price is $72.42 and its two-hundred day moving average price is $70.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.10 billion. During the same quarter last year, the company posted $0.49 earnings per share. The company's revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies announced that its board has authorized a share repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's management believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of large investors have recently added to or reduced their stakes in COO. Algert Global LLC bought a new position in Cooper Companies during the second quarter worth $7,655,000. BlackRock Inc. bought a new stake in Cooper Companies during the second quarter valued at $1,077,762,000. Heartland Advisors Inc. bought a new stake in Cooper Companies during the fourth quarter valued at $15,348,000. Tocqueville Asset Management L.P. bought a new position in shares of Cooper Companies in the 2nd quarter worth about $1,502,000. Finally, Western Standard LLC bought a new position in shares of Cooper Companies in the 2nd quarter worth about $5,228,000. Institutional investors and hedge funds own 24.39% of the company's stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.